Literature DB >> 10947851

Regulation of human myocilin/TIGR gene transcription in trabecular meshwork cells and astrocytes: role of upstream stimulatory factor.

L Kirstein1, A Cvekl, B K Chauhan, E R Tamm.   

Abstract

BACKGROUND: Mutations in the myocilin (MYOC)/TIGR gene are responsible for autosomal-dominant juvenile primary open-angle glaucoma (POAG). In patients with non-autosomal-dominant POAG, such mutations are rare, but the expression of MYOC/TIGR in the trabecular meshwork (TM) of the eye is considerably higher than in normals. We performed transfection, DNAse I footprinting, mutagenesis and electrophoretic mobility shift assays (EMSA) to identify elements responsible for the basal transcription of MYOC/TIGR in TM cells and astrocytes.
RESULTS: DNAse I footprinting experiments of the human MYOC/TIGR promoter showed a major protected area between nt -106 to -77, which was not conserved in the homologous region of the mouse myoc/tigr promoter. In addition, the TATA-box was protected, as well as at least three downstream sites, including an AP-1-like sequence. Deletion of the -106 to -77 region caused a substantial loss of functional promotor activity in all cell types. Site-directed mutagenesis and EMSA experiments revealed the presence of two regulatory elements in the -106 to -77 region. Each of these cis-elements is essential for minimal promoter activity. The 5'-half of the region contains a sequence with similarities to NF-kappaB-related sites, however, binding of NF-kappaB could not be confirmed by EMSA. The 3'-half contains a canonical E-box sequence. EMSA experiments showed that the upstream regulatory factor (USF) was binding to the E-box sequence and that the binding can be supershifted by specific antibodies.
CONCLUSIONS: Several DNA-protein binding elements contribute to a transcription of MYOC/TIGR, and USF is critically required for its basal transcription in trabecular meshwork cells and astrocytes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10947851     DOI: 10.1046/j.1365-2443.2000.00355.x

Source DB:  PubMed          Journal:  Genes Cells        ISSN: 1356-9597            Impact factor:   1.891


  8 in total

1.  Interaction of myocilin with gamma-synuclein affects its secretion and aggregation.

Authors:  Irina Surgucheva; Bum-Chan Park; Beatrice Y J T Yue; Stanislav Tomarev; Andrei Surguchov
Journal:  Cell Mol Neurobiol       Date:  2005-09       Impact factor: 5.046

Review 2.  Glaucoma-associated myocilin: a better understanding but much more to learn.

Authors:  Zachary T Resch; Michael P Fautsch
Journal:  Exp Eye Res       Date:  2008-08-29       Impact factor: 3.467

3.  Association of MYOC and APOE promoter polymorphisms and primary open-angle glaucoma: a meta-analysis.

Authors:  Hui Guo; Minghao Li; Zhe Wang; Qiji Liu; Xinyi Wu
Journal:  Int J Clin Exp Med       Date:  2015-02-15

4.  NFATc1 activity regulates the expression of myocilin induced by dexamethasone.

Authors:  Jennifer A Faralli; Ross W Clark; Mark S Filla; Donna M Peters
Journal:  Exp Eye Res       Date:  2014-11-18       Impact factor: 3.467

5.  Dexamethasone-Induced Ocular Hypertension in Mice: Effects of Myocilin and Route of Administration.

Authors:  Gaurang C Patel; Tien N Phan; Prabhavathi Maddineni; Ramesh B Kasetti; J Cameron Millar; Abbot F Clark; Gulab S Zode
Journal:  Am J Pathol       Date:  2017-02-04       Impact factor: 4.307

Review 6.  Olfactomedin domain-containing proteins: possible mechanisms of action and functions in normal development and pathology.

Authors:  Stanislav I Tomarev; Naoki Nakaya
Journal:  Mol Neurobiol       Date:  2009-06-26       Impact factor: 5.590

7.  Mammalian TBX1 preferentially binds and regulates downstream targets via a tandem T-site repeat.

Authors:  Raquel Castellanos; Qing Xie; Deyou Zheng; Ales Cvekl; Bernice E Morrow
Journal:  PLoS One       Date:  2014-05-05       Impact factor: 3.240

8.  Role of MYOC and OPTN sequence variations in Spanish patients with primary open-angle glaucoma.

Authors:  Francisco Lopez-Martinez; Maria-Pilar Lopez-Garrido; Francisco Sanchez-Sanchez; Ezequiel Campos-Mollo; Miguel Coca-Prados; Julio Escribano
Journal:  Mol Vis       Date:  2007-06-14       Impact factor: 2.367

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.